| Literature DB >> 25476518 |
Mohamed G ElBanan1, Ahmed M Amer1, Pascal O Zinn2, Rivka R Colen3.
Abstract
Glioblastoma (GBM) is the most common and most aggressive primary malignant tumor of the central nervous system. Recently, researchers concluded that the "one-size-fits-all" approach for treatment of GBM is no longer valid and research should be directed toward more personalized and patient-tailored treatment protocols. Identification of the molecular and genomic pathways underlying GBM is essential for achieving this personalized and targeted therapeutic approach. Imaging genomics represents a new era as a noninvasive surrogate for genomic and molecular profile identification. This article discusses the basics of imaging genomics of GBM, its role in treatment decision-making, and its future potential in noninvasive genomic identification.Entities:
Keywords: 1p/19q; EGFR; Genetic biomarkers; Glioblastoma; IDH1; Imaging genomics; MGMT; Radiogenomics
Mesh:
Year: 2015 PMID: 25476518 DOI: 10.1016/j.nic.2014.09.010
Source DB: PubMed Journal: Neuroimaging Clin N Am ISSN: 1052-5149 Impact factor: 2.264